Rheumatoid Arthritis: Update Bulletin #3

  • ID: 4521374
  • Newsletter
  • Region: Global
  • FirstWord Publishing
1 of 2

Business Questions:

  • How do KOLs perceive Boehringer Ingelheim’s adalimumab biosimilar, Cyltezo?
  • With three adalimumab biosimilars now approved in Europe, what concerns do prescribers have with regard to multiple biosimilar versions becoming available?
  • How do KOLs view Sandoz’s Rixathon, the second rituximab biosimilar to enter the RA space in Europe?
  • Celltrion is currently developing a subcutaneously administered infliximab biosimilar, but what need is there currently for a subcutaneous version of this product?
  • What concerns might prescribers have regarding Celltrion’s subcutaneous infliximab biosimilar?
Note: Product cover images may vary from those shown
2 of 2

Loading
LOADING...

3 of 2
Note: Product cover images may vary from those shown
Adroll
adroll